Skip to main
  1. Stocks
  2. Agenus
  3. Forecast
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Agenus is supported by a compelling BOT+BAL neoadjuvant thesis, where peer-reviewed NEST and UNICORN data showed roughly 30% pCR in MSS disease versus a much lower benchmark the ROBBIN study is powered to detect, while the FDA-agreed design could also spare about a third of the experimental arm from oxaliplatin if pCR trends hold. The balance sheet has improved materially, with about $86.9M of cash at 9/30 and runway through 3Q27, plus up to about $255M in milestone-linked warrant value, reducing near-term financing risk as 3Q revenue of $31.5M exceeded expectations and operating cash use fell to $20.1M. Its first marketing authorizations in Armenia and expanding access revenue in Europe and the Americas validate commercial traction outside the U.S., while ROBBIN’s 1Q27 first patient and 4Q27 pathologic-response interim create clear catalysts for value re-rating.

Bears say

Agenus is a high-risk, pre-commercial biotech whose value hinges on whether botensilimab plus balstilimab can prove a clinically meaningful event-free survival benefit in the planned ~850-patient ROBBIN study, since encouraging Phase I/II pathologic responses and ctDNA clearance have not yet been validated in a randomized registrational setting. The company also faces substantial regulatory and competitive pressure in the crowded MSS colorectal cancer space, where FDA approval, reimbursement, and market penetration remain uncertain even if interim data are positive. Financially, $86.9M of cash, cash equivalents, and short-term investments at 9/30/26 appears only to support operations through 3Q27 absent warrant exercise, while reliance on a possible ~$255M from milestone-linked warrants creates material dilution and refinancing risk if timelines slip.

Agenus (AGEN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Agenus (AGEN) Analyst Forecast & Price Prediction

Get the latest Agenus (AGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Agenus (AGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Agenus (AGEN) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Agenus (AGEN) Analyst Forecast & Price Prediction

Get the latest Agenus (AGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Agenus (AGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AGEN stock data and trends